A structured programme to withdraw antipsychotics among adults with intellectual disabilities: The Cornwall experience.
adults
antipsychotics withdrawal
challenging behaviour
intellectual disabilities
structured pathway
Journal
Journal of applied research in intellectual disabilities : JARID
ISSN: 1468-3148
Titre abrégé: J Appl Res Intellect Disabil
Pays: England
ID NLM: 9613616
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
12
01
2019
revised:
18
04
2019
accepted:
15
05
2019
pubmed:
14
6
2019
medline:
7
3
2020
entrez:
14
6
2019
Statut:
ppublish
Résumé
Antipsychotic medications are used among 19%-58% of adults with intellectual disabilities to manage challenging behaviour against the NICE guideline recommendations. Studies show that it is possible to completely withdraw antipsychotics in about one third of adults with intellectual disabilities and a dose reduction of 50% or more in another third. In Cornwall, over three years the present authors developed a structured pathway to withdraw antipsychotics among adults with intellectual disabilities which involved people with intellectual disabilities and their carers, GPs, community learning disability team members and pharmacists. The present authors managed to withdraw antipsychotics totally among 46.5% (33/71) and reduced over 50% of dosage in another 11.3% (8/71) of adults with intellectual disabilities. At three months follow-up no one required hospital admission or change in placement. It is possible to withdraw/reduce antipsychotics in a high proportion of adults with intellectual disabilities if a concerted effort is made involving all stakeholders from the outset.
Sections du résumé
BACKGROUND
BACKGROUND
Antipsychotic medications are used among 19%-58% of adults with intellectual disabilities to manage challenging behaviour against the NICE guideline recommendations. Studies show that it is possible to completely withdraw antipsychotics in about one third of adults with intellectual disabilities and a dose reduction of 50% or more in another third.
METHOD
METHODS
In Cornwall, over three years the present authors developed a structured pathway to withdraw antipsychotics among adults with intellectual disabilities which involved people with intellectual disabilities and their carers, GPs, community learning disability team members and pharmacists.
RESULTS
RESULTS
The present authors managed to withdraw antipsychotics totally among 46.5% (33/71) and reduced over 50% of dosage in another 11.3% (8/71) of adults with intellectual disabilities. At three months follow-up no one required hospital admission or change in placement.
CONCLUSION
CONCLUSIONS
It is possible to withdraw/reduce antipsychotics in a high proportion of adults with intellectual disabilities if a concerted effort is made involving all stakeholders from the outset.
Substances chimiques
Antipsychotic Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1389-1400Informations de copyright
© 2019 John Wiley & Sons Ltd.
Références
Ahmed, Z., Fraser, W., Kerr, M. P., Kiernan, C., Emerson, E., Robertson, J., … Thomas, J. (2000). Reducing antipsychotic medication in people with a learning disability. British Journal of Psychiatry, 176, 42-46. https://doi.org/10.1192/bjp.176.1.42
Beumer, S., & Anne Maria Maes-Festen, D. (2017).Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: Why does it fail? Lancet Psychiatry, 4, e2. https://doi.org/10.1016/S2215-0366(17)30041-X
Bowring, D. L., Totsika, V., Hastings, R. P., Toogood, S., & McMahon, M. (2017). Prevalence of psychotropic medication use and association with challenging behaviour in adults with an intellectual disability: A total population study. Journal of Intellectual Disability Research, 61(6), 604-617. https://doi.org/10.1111/jir.12359
Branford, D. (1996). Factors associated with successful or unsuccessful withdrawal of antipsychotic drug therapy prescribed for people with learning disabilities. Journal of Intellectual Disability Research, 40(4), 322-329.
Branford, D., Gerrard, D., Saleem, N., Shaw, C., & Webster, A. (2019). Stopping over-medication of people with intellectual disability, Autism or both (STOMP) in England part 1 - history and background of STOMP. Advances in Mental Health and Intellectual Disabilities, 13 (1), 31-40. https://doi.org/10.1108/AMHID-02-2018-0004
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., … Riedel, M. (2013). Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: Theoretical background and practical recommendations. CNS Drugs, 27, 545-572. https://doi.org/10.1007/s40263-013-0079-5
Christian, L., Snycerski, S. M., Singh, N. N., & Poling, A. (1999). Direct service staff and their perception of psychotropic medication in non-institutional settings for people with intellectual disability. Journal of Intellectual Disability Research, 43, 88-93.
Clarke, D. J., Kelley, S., Thinn, K., & Corbett, J. A. (1990). Psychotropic drugs and mental retardation: 1. Disabilities and the prescription of drugs for behaviour and for epilepsy in 3 residential settings. Journal of Mental Deficiency Research, 28, 229-233.
Correll, C. U. (2010). From receptor pharmacology to improved outcomes: Individualising the selection, dosing, and switching of antipsychotics. European Psychiatry, 25(suppl 2), S12-21.
de Kuijper, G., Evenhuis, H., Minderaa, R. B., & Hoekstra, P. J. (2014). Effects of controlled discontinuation of long-term used antipsychotics for behavioural symptoms in individuals with intellectual disability. Journal of Intellectual Disability Research, 58(1), 71-83. https://doi.org/10.1111/j.1365-2788.2012.01631.x
de Kuijper, G., Hoekstra, P., Visser, F., Scholte, F. A., Penning, C., & Evenhuis, H. (2010). Use of antipsychotic drugs in individuals with intellectual disability (ID) in the Netherlands: Prevalence and reasons for prescription. Journal of Intellectual Disability Research, 54(7), 659-667. https://doi.org/10.1111/j.1365-2788.2010.01275.x
Deb, S. (2013). Psychopharmacology. In E. Tsakanikos, & J. McCarthy (Eds.), Handbook of psychopathology in intellectual disability: research, practice, and policy, autism and child psychopathology series (pp. 307-324). New York, NY: Springer Science + Business Media (book chapter, 19) (Series Editor: Johnny L. Matson).
Deb, S. (2016). Psychopharmacology. In N. N. Singh (Ed.), Handbook of evidence-based practices in intellectual and developmental disabilities, evidence-based practices in behavioral health (pp. 347-381). Switzerland, Cham: Springer International Publishing.
Deb, S. (2018). The use of medication for the management of problem (challenging) behaviour in adults who have intellectual disabilities. www.intellectualdisability.info
Deb, S., Bertelli, M. O., & Rossi, M. (2019). Psychopharmacology. In M. O. Bertelli, S. Deb, K. Munir, A. Hassiotis, & L. Salvador-Carulla (Eds.), Textbook of psychiatry for intellectual disability and autism spectrum disorder. Cham, Switzerland: Springer International Publishing & Geneva, Switzerland: World Psychiatric Association (in press).
Deb, S., Clarke, D., & Unwin, G. (2006). Using medication to manage behaviour problems among adults with a learning disability: Quick Reference Guide (QRG). London, UK: University of Birmingham, MENCAP, The Royal College of Psychiatrists. http://www.ld-medication.bham.ac.uk. ISBN 0855370947
Deb, S., & Fraser, W. I. (1994). The use of psychotropic medication in people with learning disability: Towards rational prescribing. Human Psychopharmacology, 9, 259-272. https://doi.org/10.1002/hup.470090405
Deb, S., Kwok, H., Bertelli, M., Salvador-Carulla, L., Bradley, E., Torr, J., & Barnhill, J. (2009). International guide to prescribing psychotropic medication for the management of problem behaviours in adults with intellectual disabilities. World Psychiatry, 8(3), 181-186. https://doi.org/10.1002/j.2051-5545.2009.tb00248.x
Deb, S., Unwin, G., & Deb, T. (2015). Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour. Journal of Intellectual Disability Research, 59(1), 11-25. https://doi.org/10.1111/jir.12119
deKuijper, G. M., & Hoekstra, P. J. (2018). An open-label discontinuation trial of long-term, off-label antipsychotic medication in people with intellectual disability: Determinants of success and failure. The Journal of Clinical Pharmacology, 58(11), 1418-1426. https://doi.org/10.1002/jcph.1271
Doan, T. N., Lennox, N. G., Taylor-Gomez, M., & Ware, R. S. (2013). Medication use among Australian adults with intellectual disability in primary health care settings: A cross sectional study. Journal of Intellectual and Developmental Disability, 38(2), 177-181. https://doi.org/10.3109/13668250.2013.778968
England, N. H. S. (2016). Stopping Over-Medication of People with a Learning Disability (STOMPLD). www.england.nhs.uk/wp-content/uploads/2016/06/stopping-over-medication.pdf
Janowsky, D. S., Barnhill, L. J., Khalid, A. S., & Davis, J. M. (2006). Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later. Journal of Clinical Psychiatry, 67, 1272-1277. https://doi.org/10.4088/JCP.v67n0815
Janowsky, D. S., Barnhill, L. J., Khalid, A. S., & Davis, J. M. (2008). Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disability. Journal of Clinical Psychopharmacology, 28, 401-405. https://doi.org/10.1097/JCP.0b013e31817e63b9
McNamara, R., Randell, E., Gillespie, D., Wood, F., Felce, D., Romeo, R., & Kerr, M. (2017). A pilot randomised controlled trial of community-led ANtipsychotic Drug REduction for Adults with Learning Disabilities. Health Technology Assessment, 21. https://doi.org/10.3310/hta21470
National Institute for Health and Care Excellence (NICE). Challenging behaviour and learning disabilities: prevention and interventions for people with learning disabilities whose behaviour challenges. NICE Guideline 11, Methods, evidence and recommendations, May 2015. www.nice.org.uk
NHS Improvement (2018). Plan, Do, Study, Act (PDSA) cycles and the model for improvement. https://improvement.nhs.uk/documents/2142/plan-do-study-act.pdf
Niven, A., Goodey, R., Webb, A., & Shankar, R. (2018). The use of psychotropic medication for people with intellectual disabilities and behaviours that challenge in the context of a community multidisciplinary team approach. British Journal of Learning Disability, 46, 4-9. https://doi.org/10.1111/bld.12206
Oliver-Africano, P. C., Dickens, S., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., … Tyrer, P. (2010). Overcoming the barriers experienced in conducting a medication trial in adults with aggressive challenging behaviour and intellectual disabilities. Journal of Intellectual Disability Research, 54(1), 17-25. https://doi.org/10.1111/j.1365-2788.2009.01195.x
Ramerman, L., de Kuijper, G., Scheers, T., Vink, M., Vrijmoeth, P., & Hoekstra, P. J. (2019). Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo- controlled, randomised, double-blind discontinuation study. Journal of Intellectual Disability Research, 63, 418-428. https://doi.org/10.1111/jir.12584
Rojahn, J., Rowe, E. W., Sharber, A. C., Hastings, R. P., Matson, J. L., Didden, R., … Dumont, E. L. M. (2012). The behavior problems inventory-short form (BPI-S) for individuals with intellectual disabilities I: Development and provisional clinical reference data. Journal of Intellectual Disability Research, 56, 527-545.
Royal College of Psychiatrists (2016). Psychotropic drug prescribing for people with intellectual disability, mental health problems and/or behaviours that challenge: Practice guidelines. London, UK: Faculty of Psychiatry of Intellectual Disability, Faculty Report FR/ID/09, The Royal College of Psychiatrists Publication (www.rcpsych.ac.uk).
Shankar, R., Bradley-Smith, G., Brigham, P., Devapriam, J., Osborne, A., & Axby, S. (2016). Patient- and carer-held health records: Can they improve annual health checks for patients with learning disability? British Journal of General Practice, 66(645), 210-212. https://doi.org/10.3399/bjgp16X684697
Shankar, R., & Wilcock, M. (2018). Improving knowledge of psychotropic prescribing in people with intellectual disability in primary care. PLoS ONE, 13(9), e0204178.
Shankar, R., Wilcock, M., Oak, K., McGowan, P., & Sheehan, R. (2019). Stopping, rationalising or optimising antipsychotic drug treatment in people with intellectual disability and/or autism. Drug and Therapeutic Bulletins, 57(1), 10-13. https://doi.org/10.1136/dtb.2018.000009
Sheehan, R., & Hassiotis, A. (2017). Reduction or discontinuation of antipsychotics for challenging behaviour in adults with intellectual disability: A systematic review. Lancet Psychiatry, 4, 238-256. https://doi.org/10.1016/S2215-0366(16)30191-2
Sheehan, R., Hassiotis, A., Walters, K., Osborn, D., Strydom, A., & Horsfall, L. (2015). Mental illness, challenging behaviour, and psychotropic drug prescribing in people with intellectual disability: UK population-based cohort study. British Medical Journal Open, 351, h4326. https://doi.org/10.1136/bmj.h4326
Sheehan, R., Horsfall, L., Strydom, A., Osborn, D., Walters, K., & Hassiotis, A. (2017). Movement side effects of antipsychotic drugs in adults with and without intellectual disability: UK population-based cohort study. British Medical Journal Open, 7, e017406. https://doi.org/10.1136/bmjopen-2017-017406
Tsiouris, J. A., Kim, S. Y., Brown, W. T., Pettinger, J., & Cohen, I. L. (2013). Prevalence of psychotropic drug use in adults with intellectual disability: Positive and negative findings from a large-scale study. Journal of Autism & Developmental Disorders, 43, 719-731. https://doi.org/10.1007/s10803-012-1617-6
Tyrer, P., Oliver-Africano, P. C., Ahmed, Z., Bouras, N., Cooray, S., Deb, S., … Crawford, M. (2008). Risperidone, haloperidol, and placebo in the treatment of aggressive challenging behaviour in patients with intellectual disability: A randomised controlled trial. Lancet, 371, 57-63. https://doi.org/10.1016/S0140-6736(08)60072-0
Unwin, G., & Deb, S. (2008). A multi-centre audit of practice of prescribing psychotropic medication among adults with intellectual disabilities. British Journal of Learning Disabilities, 36(2), 140-143.
Unwin, G. L., & Deb, S. (2010). The use of medication to manage problem behaviours in adults with a learning disability: A National Guideline. Advances in Mental Health in Intellectual Disabilities, 4(3), 4-11. https://doi.org/10.5042/amhid.2010.0538